Sangamo Therapeutics (NASDAQ:SGMO) Price Target Cut to $5.00 by Analysts at Truist Financial

Sangamo Therapeutics (NASDAQ:SGMO) had its target price cut by Truist Financial from $7.00 to $5.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

SGMO has been the subject of a number of other research reports. Wells Fargo & Company dropped their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Jefferies Financial Group dropped their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, December 31st. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Barclays increased their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, January 2nd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $5.17.

Sangamo Therapeutics Trading Up 3.5 %

Shares of NASDAQ:SGMO opened at $1.19 on Thursday. The company’s fifty day moving average is $1.82 and its 200 day moving average is $1.31. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the previous year, the business earned ($0.34) earnings per share. As a group, sell-side analysts forecast that Sangamo Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several large investors have recently bought and sold shares of the company. Shelton Wealth Management LLC purchased a new position in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $29,000. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics during the second quarter valued at $67,000. Meritage Portfolio Management boosted its holdings in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth about $89,000. Finally, XTX Topco Ltd increased its stake in shares of Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares in the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.